ID   EFO-27
AC   CVCL_1192
SY   EFO 27; EFO27
DR   BTO; BTO:0002033
DR   CLO; CLO_0002893
DR   EFO; EFO_0006571
DR   CLDB; cl1143
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473290
DR   BioSample; SAMN03473370
DR   BioSample; SAMN10988215
DR   CCLE; EFO27_OVARY
DR   Cell_Model_Passport; SIDM01051
DR   ChEMBL-Cells; CHEMBL3308134
DR   ChEMBL-Targets; CHEMBL1075441
DR   Cosmic; 906852
DR   Cosmic; 1305326
DR   Cosmic; 1707565
DR   Cosmic-CLP; 906852
DR   DepMap; ACH-000936
DR   DSMZ; ACC-191
DR   GDSC; 906852
DR   GEO; GSM659375
DR   GEO; GSM887001
DR   GEO; GSM888070
DR   GEO; GSM1669757
DR   IARC_TP53; 21323
DR   LiGeA; CCLE_238
DR   LINCS_LDP; LCL-1521
DR   PharmacoDB; EFO27_326_2019
DR   Wikidata; Q54832067
RX   PubMed=3476184;
RX   PubMed=6405069;
RX   PubMed=12661003;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23415752;
RX   PubMed=23839242;
RX   PubMed=25485619;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 29 hours (PubMed=25984343); ~50-80 hours (DSMZ); 26.68 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=12661003; PubMed=31068700; Sanger).
CC   Sequence variation: Heterozygous for TP53 p.Arg273Cys (c.817C>T) (ClinVar=VCV000043594) (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.18%; Native American=0%; East Asian, North=1.36%; East Asian, South=0%; South Asian=0%; European, North=70.88%; European, South=27.58% (PubMed=30894373).
CC   Derived from metastatic site: Omentum.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 9,10,13,14 (Cosmic-CLP; PubMed=25877200; PubMed=30485824)
ST   CSF1PO: 9,10,13 (DSMZ)
ST   D13S317: 12,13
ST   D16S539: 11,13
ST   D18S51: 12,18
ST   D21S11: 27,30 (PubMed=25877200)
ST   D21S11: 27,30,31 (PubMed=30485824)
ST   D3S1358: 14,17
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13,15
ST   FGA: 23,26
ST   Penta D: 9
ST   Penta E: 7,10
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 13,18
DI   NCIt; C5243; Ovarian mucinous adenocarcinoma
DI   ORDO; Orphanet_398961; Mucinous adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 29
//
RX   PubMed=3476184; DOI=10.1016/0165-4608(87)90206-8;
RA   Kunzmann R., Holzel F.;
RT   "Karyotype alterations in human ovarian carcinoma cells during long-term
RT   cultivation and nude mouse passage.";
RL   Cancer Genet. Cytogenet. 28:201-212(1987).
//
RX   PubMed=6405069; DOI=10.1093/jnci/70.5.839;
RA   Simon W.E., Albrecht M., Hansel M., Dietel M., Holzel F.;
RT   "Cell lines derived from human ovarian carcinomas: growth stimulation
RT   by gonadotropic and steroid hormones.";
RL   J. Natl. Cancer Inst. 70:839-845(1983).
//
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.-F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126-2126(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//